(Q34623405)

3 August 2017

title

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes (English)

1 reference

3 August 2017

0 references

Matthias Herz

1

1 reference

3 August 2017

Flavio Gaspari

2

1 reference

3 August 2017

Norberto Perico

3

1 reference

3 August 2017

Giancarlo Viberti

4

1 reference

3 August 2017

Teresa Urbanowska

5

1 reference

3 August 2017

Michael Rabbia

6

1 reference

3 August 2017

Dominika Wieczorek Kirk

7

1 reference

3 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20837369

12 July 2024

publication date

15 September 2010

1 reference

full work available at URL

3 August 2017

https://api.elsevier.com/content/article/PII:S0167527310006273?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

https://api.elsevier.com/content/article/PII:S0167527310006273?httpAccept=text/plain

12 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

International Journal of Cardiology

12 July 2024

published in

1 reference

3 August 2017

volume

151

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

136-142

1 reference

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes

3 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

12 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential

12 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

12 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Deterioration in renal function associated with fibrate therapy

12 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Effects of fibrates on serum metabolic parameters.

12 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Safety considerations with fibrate therapy

12 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people

12 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

12 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Fibrate treatment can increase serum creatinine levels

12 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

12 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

12 July 2024

tesaglitazar

14

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus

12 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

12 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes

12 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes

12 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

12 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Possible mechanisms of the fibrate-induced increase in serum creatinine

12 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells

12 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid

12 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

PPARs in the Renal Regulation of Systemic Blood Pressure

12 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function

12 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

Ethical authorship and publishing.

12 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.IJCARD.2010.08.037

12 July 2024

Identifiers

1 reference

3 August 2017

1 reference